Promotility drugs, also called prokinetic agents, are medications that strengthen and coordinate the muscular contractions in your digestive tract, helping food move through your stomach and intestines more efficiently. They’re prescribed when the normal wave-like motion of your gut slows down or becomes disorganized, leading to symptoms like nausea, bloating, early fullness, and constipation.
How Promotility Drugs Work
Your digestive tract moves food along through rhythmic muscle contractions controlled by a network of nerves embedded in your gut wall. Promotility drugs target different receptors in this nerve network, but they all share a common goal: boosting the chemical signals that tell gut muscles to contract and pushing contents forward.
The key chemical messenger in most of these pathways is acetylcholine, which acts as an “on switch” for gut muscle contractions. Some promotility drugs increase acetylcholine levels directly. Others work by removing the brakes that normally slow digestion down. For example, dopamine is a chemical that naturally reduces stomach movement. Drugs that block dopamine’s effect on the gut essentially release the brakes, letting acetylcholine do its job. Still other drugs mimic hormones like motilin or ghrelin, which trigger strong contractions in the stomach and small intestine.
Main Classes of Promotility Drugs
Dopamine Blockers
These are the most widely prescribed promotility drugs. By blocking dopamine receptors in the gut, they reverse dopamine’s natural tendency to slow stomach and small bowel movement. Metoclopramide is the most common example and is available in the United States. Domperidone, another dopamine blocker, is widely used in other countries but is not approved for sale in the U.S. Patients who have failed other treatments can sometimes access domperidone through a special investigational program with the FDA, though the current supplier will stop distributing it after September 2025.
An important difference between the two: metoclopramide crosses into the brain, which means it can cause neurological side effects including involuntary movements of the face, tongue, or limbs, a condition called tardive dyskinesia that can become permanent. The FDA requires a boxed warning on metoclopramide, and treatment should not exceed 12 weeks. Domperidone does not cross into the brain and avoids these movement-related side effects, though it can raise prolactin levels, sometimes causing breast enlargement or milk production.
Serotonin-Based Drugs
Serotonin plays a major role in gut motility. Drugs that activate a specific serotonin receptor (the 5-HT4 receptor) in the gut wall trigger acetylcholine release from nerve cells, which stimulates intestinal contractions. Prucalopride is the best-known current example and is primarily used for chronic constipation.
This drug class has a complicated history. Earlier versions, cisapride and tegaserod, were effective but pulled from the market (in 2000 and 2007, respectively) because they also interacted with receptors in the heart, increasing the risk of dangerous heart rhythm problems. Their lack of selectivity was the core issue. Prucalopride was designed to bind almost exclusively to the 5-HT4 receptor and avoid interactions with heart tissue. Clinical data so far show no concerning cardiac signal, and the drug is generally well tolerated, with diarrhea, headache, and abdominal pain as the most common side effects.
Motilin Agonists (Macrolide Antibiotics)
This is one of the more surprising entries on the list. Erythromycin, an antibiotic, happens to mimic a gut hormone called motilin. Motilin triggers strong, sweeping contractions that move contents through the stomach and small intestine. Erythromycin binds to the same receptors as motilin and can significantly speed up gastric emptying. When used as a promotility agent, erythromycin is given at doses lower than those used to fight infections, typically around 250 mg three times daily by mouth. Azithromycin, a related antibiotic, has similar properties.
The catch is that the body tends to develop tolerance to erythromycin’s gut-stimulating effect over weeks, making it less useful for long-term treatment. It’s most often used as a short-term bridge or when other options have failed.
Ghrelin Agonists
Ghrelin is a hormone produced mainly in the stomach that stimulates appetite and increases the muscular tone of the upper stomach. Drugs that mimic ghrelin can accelerate gastric emptying, and several are in various stages of development. This class is not yet widely available but represents a different approach from the acetylcholine-focused drugs.
Acetylcholinesterase Inhibitors
These drugs work by preventing the breakdown of acetylcholine, letting it accumulate and produce stronger gut contractions. Acotiamide, available in Japan, combines this mechanism with blocking certain receptors that normally suppress acetylcholine release, giving it a dual effect. Neostigmine, a short-acting option used off-label, can accelerate gastric emptying but tends to produce irregular, somewhat uncoordinated contractions in the stomach and small bowel.
Conditions They Treat
Gastroparesis is the most common reason promotility drugs are prescribed. In gastroparesis, the stomach empties abnormally slowly, causing nausea, vomiting, bloating, and feeling full after just a few bites. Diabetes is a frequent underlying cause, but gastroparesis can also follow surgery or occur without a clear trigger. Metoclopramide and erythromycin are the two primary options in the U.S. for this condition.
Chronic constipation, particularly when it doesn’t respond to fiber and standard laxatives, is another major indication. Prucalopride is specifically approved for adults with chronic constipation who haven’t gotten adequate relief from other treatments. It works by stimulating the coordinated contractions of the colon that propel stool forward.
Gastroesophageal reflux disease (GERD) sometimes benefits from promotility drugs because they tighten the valve between the esophagus and stomach while speeding stomach emptying, reducing the amount of acid available to wash back up. Functional dyspepsia, a condition where you feel discomfort or fullness in the upper stomach without a structural cause, is also treated with prokinetics in some cases.
Side Effects by Drug Class
The side effect profile varies dramatically depending on which class of promotility drug you’re taking, which is a major factor in how doctors choose between them.
- Metoclopramide: The most significant risks are neurological. Involuntary movements, restlessness, muscle stiffness, and tardive dyskinesia can occur, especially with use beyond 12 weeks or at higher cumulative doses. It can also cause drowsiness and, less commonly, breast changes from elevated prolactin.
- Domperidone: Because it stays out of the brain, neurological side effects are rare. The main concerns are elevated prolactin (causing breast tenderness or milk production) and a small risk of heart rhythm changes at higher doses.
- Prucalopride: Generally mild side effects including diarrhea, headache, and abdominal pain, most commonly in the first days of treatment. Cardiac safety has been reassuring in clinical trials.
- Erythromycin: Nausea, abdominal cramping, and diarrhea are common. Tolerance develops over time, reducing effectiveness. There is also a risk of heart rhythm prolongation, particularly when combined with other medications that affect the heart’s electrical activity.
Why Options Are Limited
If you’re reading this article, you may have already discovered that the menu of available promotility drugs is surprisingly short, especially in the United States. Several promising drugs were removed from the market after cardiac safety concerns emerged. Cisapride was pulled in 2000 after being linked to fatal heart rhythm disturbances. Tegaserod followed in 2007 for similar cardiovascular reasons. These withdrawals made regulators and drug developers extremely cautious, and selectivity for gut-specific receptors became the priority for newer drugs.
The result is that metoclopramide, with its 12-week limit and movement disorder risks, remains the only FDA-approved promotility drug for gastroparesis in the U.S. Prucalopride is approved for chronic constipation. Erythromycin is used off-label. This limited toolkit means many patients cycle through options or use combinations, and the choice of drug often comes down to balancing effectiveness against the specific side effects each person can tolerate.